Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 11
Submit an article Journal homepage
304
Views
29
CrossRef citations to date
0
Altmetric
Original Article

Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment

Julia Carolin Stingl (formerly Kirchheiner) Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany
,
Sumit Parmar Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany
,
Ariana Huber-Wechselberger Institute of Medical and Laboratory Diagnostics, Elisabethinen Hospital Linz, Austria
,
Alexander Kainz Department of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria
,
Wilfried Renner Clinical Institute of Medical and Laboratory Diagnostics, Medical University Graz, Austria
,
Angela Seeringer Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany
,
Jürgen Brockmöller Department of Clinical Pharmacology, University Medical Center, University Göttingen, Germany
,
Uwe Langsenlehner Internal Outpatient Department, Graz, Austria
,
Peter Krippl Department of Internal Medicine, General Hospital Fürstenfeld, Austria
&
Elisabeth Haschke-Becher Institute of Medical and Laboratory Diagnostics, Elisabethinen Hospital Linz, AustriaCorrespondence[email protected]
 show all
Pages 2535-2542 | Accepted 23 Aug 2010, Published online: 17 Sep 2010

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Deirdre P Cronin-Fenton & Timothy L Lash. (2011) Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Review of Clinical Pharmacology 4:3, pages 363-377.
Read now

Articles from other publishers (28)

Farhat Jabeen, Rais Ahmad, Nuzhat Khursheed, Safeena Rashid, Aarif Ali & Showkat Ahmad Ganie. 2023. Pharmacogenomics. Pharmacogenomics 223 246 .
Miguel Trujillo-Martínez, Liliana Gómez-Flores-Ramos, Luisa María Sánchez-Zamorano, Nancy Reynoso-Noverón, Lizbeth Grimaldo, Cidronio Albavera-Hernández & Lourdes Flores-Luna. (2022) Farmacogenética en el cáncer de mama: implicaciones de los genes del citocromo p450 en la supervivencia libre de la enfermedad en las mujeres jóvenes. Revista de Senología y Patología Mamaria 35:4, pages 269-284.
Crossref
Carmen Wing Han Chan, Caixia Li, Eleven Jinnan Xiao, Minjie Li, Patrick Gladson McLeywick Phiri, Tingting Yan & Judy Yuet Wa Chan. (2022) Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Expert Reviews in Molecular Medicine 24.
Crossref
Camille Robin, Benjamin Hennart, Franck Broly, Philippine Gruchala, Geoffroy Robin & Sophie Catteau-Jonard. (2021) Could Cytochrome P450 2D6, 3A4 and 3A5 Polymorphisms Explain the Variability in Clinical Response to Clomiphene Citrate of Anovulatory PCOS Women?. Frontiers in Endocrinology 12.
Crossref
Maliheh Alimardani, Meysam Moghbeli, Azam Rastgar-Moghadam, Fatemeh Homaei Shandiz & Mohammad Reza Abbaszadegan. (2021) Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer. Current Cancer Drug Targets 21:9, pages 768-793.
Crossref
Kwan Cheol Pak, Jin-A Jung, Kyun-Seop Bae & Hyeong-Seok Lim. (2017) A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors . The Journal of Clinical Pharmacology 57:9, pages 1088-1096.
Crossref
Jie Gao, Xin Tian, Jun Zhou, Ming-Zhu Cui, Hai-Feng Zhang, Na Gao, Qiang Wen & Hai-Ling Qiao. (2017) From Genotype to Phenotype: Cytochrome P450 2D6-Mediated Drug Clearance in Humans. Molecular Pharmaceutics 14:3, pages 649-657.
Crossref
M.H. Abreu, M. Gomes, F. Menezes, N. Afonso, P.H. Abreu, R. Medeiros, D. Pereira & C. Lopes. (2015) CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?. The Breast 24:4, pages 481-486.
Crossref
Aurelia H. M. de Vries Schultink, Wilbert Zwart, Sabine C. Linn, Jos H. Beijnen & Alwin D. R. Huitema. (2015) Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clinical Pharmacokinetics 54:8, pages 797-810.
Crossref
Hitoshi Zembutsu. (2015) Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics 16:3, pages 287-296.
Crossref
Lisette Binkhorst, Ron H.J. Mathijssen, Agnes Jager & Teun van Gelder. (2015) Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping. Cancer Treatment Reviews 41:3, pages 289-299.
Crossref
Christos Markopoulos. (2014) Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. World Journal of Clinical Oncology 5:3, pages 374.
Crossref
Jin-A Jung & Hyeong-Seok Lim. (2014) Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis . Pharmacogenomics 15:1, pages 49-60.
Crossref
Deirdre P Cronin-FentonPer Damkier & Timothy L Lash. (2014) Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncology 10:1, pages 107-122.
Crossref
Wei-Peng Yong, Ross Soo & Federico Innocenti. 2014. Cancer Drug Design and Discovery. Cancer Drug Design and Discovery 55 90 .
Eugenia Ch Yiannakopoulou & Debmalya Barh. 2014. Omics Approaches in Breast Cancer. Omics Approaches in Breast Cancer 499 518 .
John Logan BlackIIIIII. 2014. Molecular Diagnostics. Molecular Diagnostics 35 54 .
Danny W. K. Lum, Pablo Perel, Aroon D. Hingorani & Michael V. Holmes. (2013) CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE 8:10, pages e76648.
Crossref
Zhiyu Zeng, Yanqiong Liu, Zhiming Liu, Jianpeng You, Zhiping Chen, Jian Wang, Qiliu Peng, Li Xie, Ruolin Li, Shan Li & Xue Qin. (2013) CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer Chemotherapy and Pharmacology 72:2, pages 287-303.
Crossref
Jennifer Karle, Juliane Bolbrinker, Silvia Vogl, Reinhold Kreutz, Carsten Denkert, Jan Eucker, Manfred Wischnewsky, Kurt Possinger & Anne C. Regierer. (2013) Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Research and Treatment 139:2, pages 553-560.
Crossref
Sara MargolinJonatan D Lindh, Linda Thorén, Hanjing Xie, Larissa Koukel, Marja-Liisa Dahl & Erik Eliasson. (2013) CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics 14:6, pages 613-622.
Crossref
Luciana B. Crotti, Fernanda Kehdy, Eduardo Tarazona-Santos & Luis A. Espinoza. 2013. Omics for Personalized Medicine. Omics for Personalized Medicine 507 527 .
Marzia Del Re, Angela Michelucci, Paolo Simi & Romano Danesi. (2012) Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treatment Reviews 38:5, pages 442-450.
Crossref
Ariana E. Huber-Wechselberger, Paul Niedetzky, Irene Aigner & Elisabeth Haschke-Becher. (2012) Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Bedeutung des CYP2D6 Polymorphismus für die Tamoxifen Therapie: eine Standortbestimmung. Wiener Medizinische Wochenschrift 162:11-12, pages 252-261.
Crossref
Daniel L. Hertz, Howard L. McLeod & William J. IrvinJrJr. (2012) Tamoxifen and CYP2D6: A Contradiction of Data. The Oncologist 17:5, pages 620-630.
Crossref
Sumit Parmar, Julia Carolin Stingl, Ariana Huber-Wechselberger, Alexander Kainz, Wilfried Renner, Uwe Langsenlehner, Peter Krippl, Jürgen Brockmöller & Elisabeth Haschke-Becher. (2011) Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Research 13:3.
Crossref
Natalie Galanina, Veerle Bossuyt & Lyndsay N. Harris. (2011) Molecular Predictors of Response to Therapy for Breast Cancer. The Cancer Journal 17:2, pages 96-103.
Crossref
J C Stingl (formerly Kirchheiner)J Brockmöller. (2011) Why, When, and How Should Pharmacogenetics Be Applied in Clinical Studies?: Current and Future Approaches to Study Designs. Clinical Pharmacology & Therapeutics 89:2, pages 198-209.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.